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DObjective: Right heart failure is a major cause of morbidity and mortality after left ventricular assist device
(LVAD) implantation. This study evaluated the approach of a cavoaortic shunt included in the LVAD circuit,
which would aim to relieve venous congestion and improve hemodynamics with preserved oxygen delivery
during induced right ventricular failure.
Methods: Right ventricular failure was induced by coronary ligation in 10 pigs. An LVAD was implanted and
a cavoaortic shunt was created from the right atrium and included in the assist circuit. Hemodynamic measures
and blood gas analyses were analyzed. Oxygen delivery and oxygen consumption were estimated.
Results: Right atrial pressure decreased from more than 20 mm Hg to 17.2 mm Hg (14.8-18.4) with the LVAD
and to 14.1 mm Hg (11.2-15.5) (P<.01) with the LVAD and cavoaortic shunt. Mean arterial pressure increased
from 70.9 mm Hg (67.6-79.8) to 81.5 mm Hg (70.8-92.6) (P ¼ .02) with addition of the shunt into the assist
circuit. Cardiac output increased from 3.5 L/min (2.6-4.2) to 4.9 L/min (3.5-5.6) (P<.01) with cavoaortic shunt-
ing. Oxygen delivery with the cavoaortic shunt was 337 mL/min (70) as compared with left ventricular assist
alone at 258 mL/min (52) (P<.01). Oxygen consumption was restored during use of the cavoaortic shunt.
Conclusions:A cavoaortic shunt combinedwith an LVADduring right ventricular failure reduces central venous
pressures, increases systemic arterial pressure, and enables increased cardiac output compared with device
therapy alone. This was feasible with preserved oxygen delivery. (J Thorac Cardiovasc Surg 2014;147:625-31)Left ventricular assist device (LVAD) therapy has become
an established treatment for end-stage heart failure.1,2 In
these patients, right ventricular (RV) failure of various
degrees is one of the most dreaded complications known
to cause significant morbidity and mortality.3,4 Today,
although efforts have been made, there is a lack of
reliable predictors of which patients will have RV failure
undergoing surgery.5,6 Irrespective of the preoperative
condition of the RV, the LVAD implantation is at times
a venture inasmuch as the evolution of RV function
during surgery is somewhat unpredictable.
Once severe RV failure occurs, the only reliable treatment
is the placement of anRVassist device (RVAD). Patientswho
receive RVADs have poorer prognoses both in short- and
long-term perspectives. However, they more commonly
have severe RV failure, venous congestion, and end-organ
failure preoperatively.3,7 We have earlier evaluated
a complementary approach to RVAD, the concept of
a modified Glenn shunt (superior vena cava to maine Department of Cardiothoracic Surgerya and Department of Anesthesiology
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The Journal of Thoracic and Capulmonary artery) in experimental RV failure.8 This ap-
proach was feasible with a positive effect on hemodynamics
such as central venous pressures and cardiac output (CO).
However, in cases of elevated pulmonary vascular resis-
tance (PVR), the concept of Glenn is not an option when RV
failure occurs during LVAD surgery.
Elevated PVR is present in some LVAD candidates as
a consequence of severe and longstanding congestive heart
failure.9-11 In these patients, the resistance in the
pulmonary vascular bed might be even further elevated
with prolonged surgery, coagulopathy, and bleeding
necessitating transfusion. This viscous circulatory state
with increasing PVR during LVAD implantation might
result in a situation that requires temporary decompression
of both the RVand the pulmonary circulation.
We sought to evaluate a complementary approach to bi-
ventricular failure that would aim at properly unloading
the RV, relieving central venous congestion, and unloading
the pulmonary circulation. We hypothesized that a cav-
oaortic shunt included in the LVAD circuit would reduce
central venous pressures and improve circulation (CO and
mean arterial pressure [MAP]) with maintained oxygen de-
livery (DO2) in acute RV failure during LVAD therapy.MATERIAL AND METHODS
The Uppsala Ethical Committee on Laboratory Animal Research ap-
proved the study and all animals received humane care in compliance
with the European Convention on Animal Care.rdiovascular Surgery c Volume 147, Number 2 625
Abbreviations and Acronyms
CaO2 ¼ arterial oxygen content
CO ¼ cardiac output
DO2 ¼ oxygen delivery
LA ¼ left atrium
LV ¼ left ventricular
LVAD ¼ left ventricular assist device
MAP ¼ mean arterial pressure
PaO2 ¼ arterial oxygen partial pressure
PVR ¼ pulmonary vascular resistance
RA ¼ right atrium
RV ¼ right ventricular (ventricle)
RVAD ¼ right ventricular assist device
SaO2 ¼ arterial oxygen saturation
SvO2 ¼ mixed venous oxygen saturation
VO2 ¼ oxygen uptake
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DAnesthesia
The study comprised 11 pigs of Swedish country breed with a mean
weight of 34.9 kg (1.6).
Anesthesia was induced by a subcutaneous injection of xylazine (Rom-
pun, 2.2 mg/kg; Bayer A/S, Lyngby, Denmark) and tiletamine/zolazepam
(Zoletil, 100 6.0 mg/kg; Virbac SA, CarrosCedex, France) and maintained
by infusion of a buffered glucose solution carrier (Rehydrex with glucose,
25 mg/mL; Fresenius Kabi AB, Uppsala, Sweden) with ketamine, 30 mg/
kg/h (Ketaminol Vet 100 mg/mL; Intervet AB, Stockholm, Sweden), fen-
tanyl, 0.04 mg/kg/h (Fentanyl 50 mg/mL; B Braun Medical AB, Danderyd,
Sweden), midazolam, 0.1 mg/kg/h (Midazolam Hameln, 1 mg/mL; Algo-
lPharma AB, Kista, Sweden), and pancuronium bromide, 0.3 mg/kg/h
(Pavulon 2 mg/mL; ScheringPlough AB, Stockholm, Sweden).
Body temperature was controlled with a heating pad, aiming for a core
temperature of 37C.
The pigs were intubated and mechanically ventilated with 21% oxygen
by a Siemens Servo-i ventilator (Maquet GmbH & Co KG, Rastatt,
Germany). Volume-controlled ventilation was used aiming for an arterial
PCO2 within the range of 5.0 to 5.5 kPa, and a positive end-expiratory pres-
sure of 5 cmH2Owas applied. The bladder was catheterized with a silicone
catheter.
A catheter was inserted through the right external jugular vein (BD
Careflow 17G; Becton-Dickinson AB, Stockholm, Sweden) for central ve-
nous pressure, blood sampling, and drug administration. A thermodilution
pulmonary artery cathether (BD Criticath Pulmonary Artery/Thermodilu-
tion Catheter; Becton-Dickinson) was introduced through the right external
jugular vein and advanced to the pulmonary artery for measurements of CO
and mixed venous oxygen saturation (SvO2).
A catheter was inserted into the left femoral artery for continuous mon-
itoring of oxygen saturation (PaO2), blood gas extraction, and for arterial
blood pressure with a pressure transducer (BD Careflow 20G; Becton-
Dickinson).
Surgical Preparation
Amedian sternotomy was performed. The pericardium was opened and
pericardial stay sutures were placed. The azygos and hemiazygos veins
were ligated. Pressure transducer catheters were surgically placed in the
right atrium (RA), RV, and the left atrium (LA). The catheters were secured
with fine sutures and connected to a monitoring system (Dr€ager Infinity
Delta; Dr€ager Medical; L€ubeck, Germany). Animals were heparinized
with 7500 IU once and repeatedly every 2 hours with 5000 IU. The RA626 The Journal of Thoracic and Cardiovascular Surgwas cannulated with a 24F venous cannula (Malleable Single Stage Venous
Cannula; Edwards Lifesciences, Irvine, Calif), as shown in Figure 1. The
left ventricular (LV) apex was cannulated with a 28F venous cannula (Mal-
leable Single Stage Venous Cannula; Edwards Lifesciences). A 16F arterial
cannula (FemFlex; Edwards Lifesciences) was inserted into the ascending
aorta. All cannulas were secured with purse-string sutures. A Bio-Pump
flow probe connector (Medtronic, Inc, Minneapolis, Minn) was connected
to the RA cannula. The RA and the LV apical cannula were deaired and
connected with a Y-connector to the inflow tubing of a preprimed Bio-
Pump connector (Medtronic). The aortic cannula was deaired and con-
nected to the outflow tubing of the Bio-Pump connector.
Experimental Protocol
RV failure was created by subsequent ligation of 4 to 6 branches of the
right coronary artery and all visible branches to the RV from the left coro-
nary artery. The RVwas further challenged with volume overload achieved
by rapid infusion of 2000 mL HESRA (Baxter AB, Knivsta, Sweden). RV
failure was considered present at an RA pressure of 20 mm Hg or more.
When the pressure was 20 mm Hg or more, the LVAD was started and
set to a flow corresponding to the baseline CO value. The RA cannula was
opened and the flow through this cannula was set to one third of total LVAD
flow by an adjustable clamp, so that one third of the CO was shunted from
the RA, via the Bio-Pump connector, into the ascending aorta. After 20
minutes of shunting, measurements were made.
Measurements
The experimental protocol required right heart failure to be established.
Data were recorded during 4 time periods: (1) baseline, (2) severe RV fail-
ure, (3) LVAD with closed RA cannula, and (4) LVAD and one third of the
total CO through the RA cannula (Figure 1).
A 20-minute stabilization period was followed by repeated measure-
ments every minute for 5 consecutive minutes.
Standard lead II electrocardiogram, systemic arterial blood pressure,
RA pressure, RV pressure, LA pressure, and pulmonary artery pressure
were monitored continuously and recorded. CO was measured, using
the thermodilution technique. During LVAD and LVAD with cavoaortic
shunting, the total LVAD flow was used as CO. Blood samples were col-
lected at the same time periods for arterial and venous blood gas analysis.
Arterial blood gases, hemoglobin concentration, and SvO2 were measured
with an ABL 500 Radiometer (Radiometer Medical ApS, Bronshoj,
Denmark).
The arterial oxygen content (CaO2) was calculated using the formula
(0.0138 3 hemoglobin 3 SaO2) þ (0.0031 3 PaO2) and the DO2 using
the formula Cao2 3 CO 3 10. VO2 was calculated using the formula
Vo2 ¼ CO 3 (Cao2  Cvo2).
Statistical Analysis
Nonparametric tests were used inasmuch as normality assumption was
subject to question. For hemodynamic measurements such as RA pressure,
RV pressure, LA pressure, MAP, and CO, the value for each animal was the
mean of all measurements of each period and data were expressed as me-
dians with 95% confidence interval. For blood gas analysis, and calculated
parameters (CaO2 and DO2), data are expressed as means (SD). The Wil-
coxon matched pairs signed-rank test was used to compare differences be-
tween the periods: baseline, RV failure, RV failure and LVAD without
shunt, and RV failure and LVAD with shunt. Statistical calculations were
performed with the SPSS statistical package 20.0 (SPSS, Inc, Chicago, Ill).RESULTS
All 10 animals survived the study period and constituted
the study group. RV failure was achieved in all pigs leading
to significantly elevated right-sided filling pressures.ery c February 2014
FIGURE 1. Animal preparation and flow chart of the experimental protocol in the model of right ventricular failure in pigs (n ¼ 10). An LVAD was im-
planted and a cavoaortic shunt was created from the right atrium (the cannulas into the superior vena cava) to the aorta. LVAD, Left ventricular assist device.
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After induced RV failure, CO decreased from 3.4 L/min
(2.6-4.2) to 2.0 L/min (1.5-2.5) (P ¼ .01; Table 1). Mean
RA pressure increased from 10.8 mmHg (9.0-11.0) at base-
line to 20.4 mm Hg (20.0-22.2) (P<.01) at RV failure as
depicted in Figure 2 and Table 1. The diastolic RV pressure
increased from 9.0 mm Hg (8.7-10.3) at baseline to 13.4
mm Hg (12.4-16.6) (P<.01; Figure 2).
No significant changes were observed in the LA pressure
or systemic MAP. In addition, the SaO2 and SvO2, remained
unchanged during establishment of RV failure (Figure 3).
The DO2 was reduced by 43% from 387 mL/min (96) at
baseline to 171 mL/min (40) (P< .01) at RV failure
(Table 1 and Figure 4). Finally, oxygen uptake (VO2) was re-
duced from 180 mL/min (53) to 86 mL/min (17)
(P<.01) during RV failure (Figure 4).LVAD Therapy Only
When LVAD therapy was instituted, the pump was set to
produce a CO that was equal to the baseline value at 3.4 L/
min (2.6-4.2). This resulted in a decrease in RA pressure
from 20.4 mm Hg (20.0-22.2) to 17.2 mm Hg (14.8-18.4)
(P< .01; Figure 2). Also, the diastolic RV pressure de-
creased from 13.4 mm Hg (12.4-16.6) at RV failure toThe Journal of Thoracic and Ca11.9 mm Hg (11.0-15.0) (P ¼ .02) during LVAD therapy,
as shown in Table 1 and Figure 2.
Compared with the period with RV failure, MAP was un-
affected, but both DO2 and VO2 were increased when LVAD
therapy was put in use, as depicted in Table 1.LVAD and Cavoaortic Shunt
There was an increase in CO when LVAD therapy was
combined with the cavoaortic shunt as compared with
LVAD alone, from 3.5 L/min (2.7-4.0) to 4.9 L/min (3.5-
5.6) (P<.01; Table 1). The RA pressure decreased even fur-
ther when the cavoaortic shunt was put in use to 14.1mmHg
(11.2-15.5) (P<.01) as compared with LVAD alone (Table 1
andFigure 2). TheRVpressures did not change significantly,
nor did the LA pressure with use of the shunt. There was an
elevation ofMAP from 70.9 mmHg (67.6-79.8) with LVAD
only to 81.5 mm Hg (70.8-92.6) (P ¼ .02) with the use of
LVAD and cavoaortic shunt, as described in Table 1.
A decrease in SaO2 from 94.4% (6.4) to 86.2% (6.5)
(P<.01) was observed when the cavoaortic shunt was in
use. The SvO2, on the other hand, remained unchanged, as
shown in Figure 3 and Table 1. The DO2 during LVAD
and the cavoaortic shunt were higher when compared
with LVAD only, at 337 mL/min (70) and 258 mL/minrdiovascular Surgery c Volume 147, Number 2 627
TABLE 1. Hemodynamic values, blood gas values, and calculations of CaO2 and DO2 at baseline, RV failure, LVAD treatment, and LVAD treatment
plus cavoaortic shunting (n ¼ 10)
Baseline
Versus
(P value) Right heart failure
Versus
(P value) LVAD
Versus
(P value) LVAD plus cavo-aortal shunt
RAP (mm Hg) 10.8 (9.0-11.0) <.01 20.4 (20.0-22.2) <.01 17.2 (14.8-18.4) <.01 14.1 (11.2-15.5)
DRVP (mm Hg) 9.0 (8.7-10.3) <.01 13.4 (12.4-16.6) .02 11.9 (11.0-15.0) .41 11.6 (10.0-16.0)
SRVP (mm Hg) 31.9 (27.8-41.8) .04 37.2 (35.6-39.2) .17 35.7 (34.3-43.8) .45 35.9 (32.2-43.8)
mPAP (mm Hg) 22.4 (18.8-24.8) <.01 28.6 (26.4-31.2) .06 23.9 (21.0-31.4) .72 24.0 (19.8-34.8)
LAP (mm Hg) 15.8 (13.0-20.0) .11 17.2 (15.3-26.2) <.01 13.6 (11.0-16.2) .42 12.1 (10.5-17.8)
MAP (mm Hg) 65.4 (60.8-71.8) .07 71.7 (62.0-79.6) .51 70.9 (67.6-79.8) .02 81.5 (70.8-92.6)
CO (L/min) 3.4 (2.6-4.2) <.01 2.0 (1.5-2.5) N/A N/A N/A N/A
LVAD (L/min) N/A N/A N/A N/A 3.5 (2.7-4.0) <.01 4.9 (3.5-5.6)
DO2 (mL/min) 387 (96) <.01 171 (40) <.01 258 (52) <.01 337 (70)
VO2 (mL/min) 180 (53) <.01 86 (17) <.01 138 (32) .07 160 (39)
SaO2 (%) 96.0 (2.2) .51 95.2 (3.8) .65 94.4 (6.4) <.01 86.2 (6.5)
SvO2 (%) 50.2 (11.8) .17 46.4 (8.2) .84 44.2 (6.2) .24 44.1 (12.3)
CaO2 (mL/dL) 11.5 (1.5) <.01 8.6 (0.9) <.01 7.5 (0.6) .16 7.3 (1.1)
CvO2 (mL/dL) 6.0 (1.4) <.01 4.2 (0.9) .02 3.5 (0.3) .76 3.8 (1.6)
Hemoglobin (g/dL) 8.7 (1.3) <.01 6.6 (0.8) <.01 5.8 (0.6) .06 6.1 (1.0)
PaO2 (kPa) 13.6 (3.2) .39 12.9 (2.7) .36 12.3 (2.5) <.01 7.7 (0.9)
PaCO2 (kPa) 5.0 (0.5) .42 5.1 (0.7) .76 5.2 (0.6) .09 5.4 (0.8)
pH 7.46 (0.06) .05 7.44 (0.06) .30 7.43 (0.07) .55 7.43 (0.07)
SBE (mmol/L) 2.9 (2.2) <.01 1.1 (1.4) .33 1.5 (2.0) .04 2.0 (2.2)
Hemodynamic values presented as median with 95% confidence interval, and blood gas derived values as mean standard deviation.Cao2, Arterial oxygen content;Do2, oxygen
delivery; RV, right ventricular; LVAD, left ventricular assist device; RAP, right arterial pressure; DRVP, diastolic right ventricular pressure; SRVP, systolic right ventricular pres-
sure; mPAP, mean pulmonary artery pressure; LAP, left atrial pressure; MAP, mean arterial pressure; CO, cardiac output; Vo2, oxygen uptake; Sao2, arterial oxygen saturation;
Svo2, mixed venous oxygen saturation; Cvo2, venous oxygen content; Pao2, arterial oxygen partial pressure; Paco2, arterial carbon dioxide partial pressure; SBE, arterial standard
base excess; N/A, not applicable.
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D(52), respectively (P<.01; Figure 4 and Table 1). More-
over, the VO2 was unaffected at 138 mL/min (32) with
LVAD only as compared with 160 mL/min (39) when
the shunt was in use (P ¼ .07).Blood Gas Analysis
Initially, the hemoglobin decreased during the experi-
ment, but then there was a slight increase in hemoglobin
during cavoaortic shunting, as shown in Table 1. In addition,
the CaO2 decreased throughout the experiment from0
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FIGURE 2. Right atrial and right ventricular pressures at baseline, RV
failure, LVAD, and LVAD þ cavoaortic shunt (n ¼ 10). RAP, Right atrial
pressure; DRVP, diastolic right ventricular pressure; SRVP, systolic right
ventricular pressure; LVAD, left ventricular assist device.
628 The Journal of Thoracic and Cardiovascular Surg11.5 mL/dL (1.5) at baseline to finally 7.3 mL/dL
(1.1) (P<.01) with LVAD and use of the cavoaortic shunt,
as shown in Table 1. Arterial standard base excess decreased
from baseline to RV failure but increased during LVAD to
1.5 mmol/L (2.0) and even further when the cavoaortic
shunt was used to 2.0 mmol/L (2.2) (P ¼ .03; Table 1).
DISCUSSION
This experimental study shows that a cavoaortic shunt
combined with LVAD therapy reduces central venous pres-
sure, increases MAP, and enables increased CO when com-
pared with LVAD without the shunt in a model of induced
RV failure. This was feasible with preserved systemic DO2.
A cavoaortic shunt included in the LVAD circuit
increased systemic DO2 by approximately 30% when com-
pared with LVAD alone in a situation with severe RV fail-
ure. The cavoaortic shunt produced a level of DO2 at 87%
of the baseline value as compared with 66% with LVAD
alone. Interestingly, this level of DO2 was accomplished
even though nonsaturated blood (shunt flow) was added
into the arterial circulation. We believe that the main reason
for this increase in DO2 is the increase in CO, which is en-
abled by the cavoaortic shunt added into the LVAD circuit.
This increase in CO was not possible to obtain without the
shunt inasmuch as the failing RV is the limiting factor, un-
able to increase its workload.Moreover, in a clinical setting,
where the 30% reduction in hemoglobin, which occurredery c February 2014
FIGURE 3. Systemic oxygen saturation (arterial and venous) at baseline,
right ventricular failure, LVAD, and LVAD þ cavoaortic shunt (n ¼ 10).
Sao2, Arterial oxygen saturation; Svo2, venous oxygen saturation; LVAD,
left ventricular assist device.
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transfusion, the DO2 with the shunt would most certainly
be even further improved. Furthermore, the SvO2 is low
but sustained throughout the experiment despite the fact
that one third of CO is shunted directly into the arterial cir-
culation. In addition, VO2 decreases during RV failure and is
restored during LVAD and cavoaortic shunt. Making the
assumption that oxygen demand is constant throughout
the experiment, this reflects increased tissue oxygenation
during shunting.
Consequently, the addition of a cavoaortic shunt into the
LVAD circuit enables an increase in CO and thereby sys-
temic DO2 in a state of severe RV failure.
An increasing number of studies propose alternative
strategies to conventional RVADs.3,4,12-14 For example,
the use of extracorporeal centrifugal pumps as temporary
RVADs is reported more frequently.12,13 In our model, the
idea is to circumvent the pulmonary circulation to unload
the RA and RV, relieve further congestion of the
pulmonary vascular bed, and allow adequate filling of the
LVAD. In a recent study, a similar concept was evaluated
with a bypass from the RA to the LA,15 and this shunt could
successfully reverse RV failure, increase MAP, and reduce
central venous pressures. However, in that experimentalFIGURE 4. Oxygen delivery (Do2) and oxygen consumption (Vo2) at
baseline, right ventricular failure, LVAD, and LVAD þ cavoaortic shunt
(n ¼ 10). LVAD, Left ventricular assist device.
The Journal of Thoracic and Camodel, the interatrial shunt was not evaluated together
with LVAD treatment and the system contained an oxygen-
ator. The inclusion of the shunt into the LVAD circuit adds
additional information, which we believe motivates our
study. Moreover, Slater and associates16 have previously
demonstrated the feasibility of right-to-left shunting to re-
duce right-sided filling pressures in experimental RV fail-
ure, also without LVAD treatment. They compared central
with peripheral shunting with no statistical difference.
They concluded that in a situation with normal pulmonary
resistance a shunt of almost 50% can be tolerated with sus-
tained SaO2. Also, Goldstein and colleagues
17 conducted
a similar study with venoarterial shunting, also with
measures of arterial saturation only. However, SaO2 is not
a reliable sole indicator of end-organ perfusion, and no
estimations of actual systemic DO2 were performed in these
studies. Finally, a case report from Toole and coworkers18
illustrates a clinical biventricular assist device situation
with escalation of pulmonary pressures not responsive to
medical management. They successfully used a right-to-
left shunt to circumvent the pulmonary circulation.
Although the field of assist device treatment has made
great progress over the past 10 years, preoperative RV fail-
ure is associated with poor results. Preoperative RV failure
reduces survival to transplant in LVAD patients from 85%
to approximately 57%.10 Preoperative prediction of RV
failure is still somewhat unreliable, and attempts to develop
useful preoperative risk scores are still a struggle. Once
present, RV failure is associated with increased periopera-
tive bleeding, more blood transfusions, higher mortality
and morbidity, increased incidence of dialysis, worsening
of renal and liver function, and increased postoperative
lengths of stay.19,20 We8 have recently shown improved he-
modynamics and reduction of central venous pressures in
RV failure with volume exclusion of the RVwith a modified
Glenn connection (shunt from the superior vena cava to the
pulmonary artery). However, the concept of a Glenn con-
nection in RV failure requires normal resistance in the pul-
monary vascular bed inasmuch as the shunt is not driven
mechanically. Thus the Glenn procedure is not an option
in patients with increased PVR.
The reestablishment of CO that an LVAD offers without
relieving venous congestion may not necessarily avert the
clinical state of end-organ failure. There has been a concep-
tual shift regarding the view of end-organ function in pa-
tients with heart failure implying that end-organ function
such as liver and kidney is even further worsened by high
venous pressures than solely on the impairment of CO.Mul-
lens and associates,21 in a study of patients with regular
heart failure, showed that preservation of CO without re-
lieving central venous pressures may not avert development
of worsening renal function. The addition of the cavoaortic
shunt into the LVAD circuit in our model reduced the central
venous pressures even further than use of the LVAD only. Inrdiovascular Surgery c Volume 147, Number 2 629
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accomplish an adequate reduction of central venous pres-
sures during RVAD treatment. If PVR is even further
increased owing to cardiopulmonary bypass and blood
transfusion,22 the congestion in the pulmonary vascular
bed increases and even the RVAD treatment will resolve
in suboptimal loading of the LVAD, inasmuch as the trans-
pulmonary blood flow will be the limiting factor. In these
desolate cases, a bypass of both the RV and the pulmonary
vascular bed might offer a beneficial clinical situation inas-
much as it will unload the pulmonary circulation and
thereby relieve further pulmonary congestion. The clinical
situation in which a cavoaortic shunt could be of use could
be pulmonary dysfunction owing to an increase in PVR
(nonresponsive to medical treatment), as described in the
previously mentioned case report on a patient with a biven-
tricular assist device.18
The major advantage of the cavoaortic shunt included in
the LVAD circuit, compared with standard RVAD place-
ment, is the simplicity of its removal. Multiple reoperations
in these critically ill patients are preferably avoided. In the
setting of biventricular failure after cardiopulmonary
bypass, the addition of an RA cannula to the LVAD circuit
is a very simple and safe method to decompress the RV
without the need to use a separate pump and/or oxygenator.
There is no need for cannulation of the RV, which can be
technically complicated. When the RV recovers, the clamp
on the RA cannula enables controlled weaning and the RA
cannula can easily be removed. Furthermore, if the oxygen
demand increases, it is simple to insert an oxygenator in the
system and thereby provide excellent oxygenation support.
Moreover, our findings suggest that current guidelines rec-
ommending closing of atrial septal defects to prevent shunt-
ing and hypoxia can be discussed. Given the overall poor
state of health of the typical LVAD candidate, the shorten-
ing of the surgical procedure and bypass time is of
importance.
Limitations
Themajor limitation of our study is that the long-term pa-
tency of the results cannot be secured in this model of acute
RV failure. The effects of shunting on PaO2 and blood pH
may not fully manifest during the time course studied. In
addition, the use of pressure-volume loops or echocardiog-
raphy could have allowed for assessment of RV volumes
and loading conditions. The DO2 is a calculated based on
CO and CaO2. A more reliable method to measure the actual
perfusion of end organs would secure data regarding the
actual state of perfusion.
An additional limitation is that each animal acts as its
own control throughout the protocol. This makes the mea-
surements not completely comparable owing to the physio-
logic changes that might occur in response to the various
steps of the protocol. Finally, the cavoaortic approach630 The Journal of Thoracic and Cardiovascular Surgshould be compared and validated to a model with classic
RVAD or extracorporeal membrane oxygenation.
In conclusion, a cavoaortic shunt included in the LVAD
circuit improved hemodynamics and enabled increased
CO, compared with LVAD alone, in an experimental model
of RV failure. Moreover, the shunt decreased central venous
pressures even further than only LVAD. This approach was
feasible with preserved DO2. The concept of a right-to-left
shunt included in the LVAD circuit can be used as short-
term support for RV failure when there is a need for RV sup-
port in combination with decompression of a congested
pulmonary vascular bed.References
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